Addressing acquired resistance through novel combination strategies
Sometimes it may seem as though the hottest – and often only things – which get attention these days are IO related, while the good old fashioned targeted therapies are ignored.
St Charles Streetcar, New Orleans LA
Do so at your peril, folks, because there’s a lot of useful data coming through these days exploring novel combination approaches to overcome acquired resistance and improve outcomes for people with various advanced cancers!
In this post, we take a look at some emerging preclinical data from the annual meeting of AACR in New Orleans, which either has led to new early stage combination trials in people with certain advanced cancers or will be starting soon.
The good news is the science is solid and the need for novel combinations in these settings is a high one – it’s time to get on board and learn about these important developments…
BSB subscribers can read our latest conference coverage from AACR plus commentary and analysis – you can either log-in or click to access.
This content is restricted to subscribers
